Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

This study tests whether adding a drug called venetoclax to the preparation regimen (conditioning) before a stem cell transplant improves outcomes for people with blood cancers undergoing a type of transplant that uses a less-intensive conditioning approach. **You may be eligible if...** - You are 18 or older with a blood cancer such as leukemia, lymphoma, myelodysplastic syndrome (MDS), or multiple myeloma - You are planned to undergo a stem cell transplant with a reduced-intensity (non-myeloablative) conditioning regimen - You have a matched stem cell donor available (10/10 HLA match, related or unrelated) - Your kidney and liver function are adequate **You may NOT be eligible if...** - You are not planned for a stem cell transplant - You do not have a suitable matched donor - Your kidney or liver function is too impaired - Your cancer type is not one of those specified Talk to your doctor to see if this trial is right for you.